{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:29:16Z","timestamp":1792045756777,"version":"4.4.0"},"reference-count":32,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>MHAA4549A, a human monoclonal antibody targeting the hemagglutinin stalk region of influenza A virus (IAV), is being developed as a therapeutic for patients hospitalized with severe IAV infection. The safety and efficacy of MHAA4549A were assessed in a randomized, double-blind, placebo-controlled, dose-ranging study in a human IAV challenge model. One hundred healthy volunteers were inoculated with A\/Wisconsin\/67\/2005 (H3N2) IAV and, 24 to 36 h later, administered a single intravenous dose of either placebo, MHAA4549A (400, 1,200, or 3,600 mg), or a standard oral dose of oseltamivir. Subjects were assessed for safety, pharmacokinetics (PK), and immunogenicity. The intent-to-treat-infected (ITTI) population was assessed for changes in viral load, influenza symptoms, and inflammatory biomarkers. MHAA4549A was well tolerated in all IAV challenge subjects. The 3,600-mg dose of MHAA4549A significantly reduced the viral burden relative to that of the placebo as determined by the area under the curve (AUC) of nasopharyngeal virus infection, quantified using quantitative PCR (98%) and 50% tissue culture infective dose (TCID<jats:sub>50<\/jats:sub>) (100%) assays. Peak viral load, duration of viral shedding, influenza symptom scores, mucus weight, and inflammatory biomarkers were also reduced. Serum PK was linear with a half-life of \u223c23 days. No MHAA4549A-treated subjects developed anti-drug antibodies. In conclusion, MHAA4549A was well tolerated and demonstrated statistically significant and substantial antiviral activity in an IAV challenge model. (This study has been registered at ClinicalTrials.gov under identifier NCT01980966.)<\/jats:p>","DOI":"10.1128\/aac.01154-17","type":"journal-article","created":{"date-parts":[[2017,8,15]],"date-time":"2017-08-15T00:40:16Z","timestamp":1502757616000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":76,"title":["Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model"],"prefix":"10.1128","volume":"61","author":[{"given":"Jacqueline M.","family":"McBride","sequence":"first","affiliation":[{"name":"Genentech, Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy J.","family":"Lim","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Burgess","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Deng","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Derby","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Maia","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Horn","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Allakos, Inc., San Carlos, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sheinson","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyin","family":"Chen-Harris","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Newton","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Fillos","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Nazzal","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie M.","family":"Rosenberger","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maikke B.","family":"Ohlson","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Lambkin-Williams","sequence":"additional","affiliation":[{"name":"hVIVO, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hosnieh","family":"Fathi","sequence":"additional","affiliation":[{"name":"hVIVO, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Harris","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge A.","family":"Tavel","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","unstructured":"World Health Organization. 2016. Influenza (seasonal) fact sheet. http:\/\/www.who.int\/mediacentre\/factsheets\/fs211\/en\/. Accessed 17 August 2015."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/655904"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir648"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2059"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.11.1333"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200115050-00003"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00474-10"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)83026-X"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/314904"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02288-1"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2013.06.004"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005702"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/371037a0"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.56.070187.002053"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00607-16"},{"key":"e_1_3_3_17_2","volume-title":"Clinical safety and efficacy of MHAA4549A, a novel monoclonal antibody for the treatment of severe influenza A: results of a randomized, double-blind, placebo-controlled clinical trial, abstr 2061","author":"McBride J","year":"2015","unstructured":"McBride J RosenbergerC TavelJ DengR DerbyM BurgessT ChaiN ParkS XuM SwemL. 2015. Clinical safety and efficacy of MHAA4549A, a novel monoclonal antibody for the treatment of severe influenza A: results of a randomized, double-blind, placebo-controlled clinical trial, abstr 2061. Abstr 2015 Keystone Symp Conf Viral Immun, Breckenridge, CO."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a113246"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2006.050875"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02519.x"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0564-y"},{"key":"e_1_3_3_22_2","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1177\/135965350501000805","article-title":"Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment","volume":"10","author":"Barroso L","year":"2005","unstructured":"Barroso L TreanorJ GubarevaL HaydenFG. 2005. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir Ther10:901\u2013910.","journal-title":"Antivir Ther"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.13.1240"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu539"},{"key":"e_1_3_3_25_2","volume-title":"Population pharmacokinetic and viral dynamic modeling of VIS410, a monoclonal antibody against influenza A virus in a human challenge model, abstr 3648","author":"Patel K","year":"2017","unstructured":"Patel K SmithPF DallG LovernM SloanS TrevejoJ HershbergerE. 2017. Population pharmacokinetic and viral dynamic modeling of VIS410, a monoclonal antibody against influenza A virus in a human challenge model, abstr 3648. Abstr 2nd Annu Meet ASM Microbe, New Orleans, LA."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu543"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2612"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw262"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv195"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2012.643868"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1742"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01657-16"},{"key":"e_1_3_3_33_2","volume-title":"Numerical methods","author":"Dey S","year":"2013","unstructured":"Dey S GuptaS. 2013. Numerical methods. McGraw Hill Education (India) Private Limited, New Delhi, India."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01154-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01154-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T05:31:10Z","timestamp":1659331870000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01154-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1128\/AAC.01154-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.01154-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"2017-06-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01154-17"}}